| MeSH term | MeSH ID | Detail |
|---|---|---|
| Lung Diseases | D008171 | 37 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Mycobacterium Infections | D009164 | 7 associated lipids |
| Sarcoidosis | D012507 | 13 associated lipids |
| Hepatolenticular Degeneration | D006527 | 3 associated lipids |
| Hyperglycemia | D006943 | 21 associated lipids |
| Carcinoma, Squamous Cell | D002294 | 14 associated lipids |
| Skin Neoplasms | D012878 | 12 associated lipids |
| Burns | D002056 | 34 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Donners MM et al. | Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE-/- mice. | 2005 | Am. J. Transplant. | pmid:15888024 |
| Singh K et al. | Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. | 2014 | Am. J. Transplant. | pmid:25359003 |
| Dugast E et al. | Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. | 2016 | Am. J. Transplant. | pmid:27367750 |
| Tang Q | Pharmacokinetics of therapeutic Tregs. | 2014 | Am. J. Transplant. | pmid:25358900 |
| Wen X et al. | Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. | 2016 | Am. J. Transplant. | pmid:27137884 |
| Sikma MA et al. | Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation. | 2015 | Am. J. Transplant. | pmid:26053114 |
| Ellis CL and Racusen LC | Mild rise in creatinine six months post kidney transplant. | 2012 | Am. J. Transplant. | pmid:22845913 |
| de Fontbrune FS et al. | Veno-occlusive disease of the liver after lung transplantation. | 2007 | Am. J. Transplant. | pmid:17697264 |
| Abdelmalek MF et al. | Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. | 2012 | Am. J. Transplant. | pmid:22233522 |
| Boudjema K et al. | Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. | 2011 | Am. J. Transplant. | pmid:21466650 |
| Knechtle SJ | Guidance for liver transplant immunosuppression. | 2011 | Am. J. Transplant. | pmid:21466652 |
| Gupta G et al. | Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. | 2015 | Am. J. Transplant. | pmid:25988397 |
| Wang Q et al. | Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion. | 2004 | Am. J. Transplant. | pmid:15084166 |
| Schubert M et al. | Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. | 2004 | Am. J. Transplant. | pmid:15084173 |
| ter Meulen CG et al. | Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. | 2004 | Am. J. Transplant. | pmid:15084178 |
| Borrows R et al. | Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. | 2004 | Am. J. Transplant. | pmid:15476485 |
| Silva HT et al. | Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. | 2013 | Am. J. Transplant. | pmid:24266969 |
| Ricciardelli I et al. | Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy. | 2013 | Am. J. Transplant. | pmid:24266973 |
| Hernández-Fisac I et al. | Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. | 2007 | Am. J. Transplant. | pmid:17725683 |
| Suszynski TM et al. | Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. | 2013 | Am. J. Transplant. | pmid:23432755 |
| Damon C et al. | Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. | 2017 | Am. J. Transplant. | pmid:27597269 |
| Ferguson R et al. | Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. | 2011 | Am. J. Transplant. | pmid:21114656 |
| Shuker N et al. | A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation. | 2016 | Am. J. Transplant. | pmid:26714287 |
| Frassetto LA and Benet LZ | Pharmacogenomics and transplantation: where are we? | 2004 | Am. J. Transplant. | pmid:15147415 |
| MacPhee IA et al. | The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. | 2004 | Am. J. Transplant. | pmid:15147425 |
| Artz MA et al. | Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. | 2004 | Am. J. Transplant. | pmid:15147428 |
| Mujtaba MA et al. | Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. | 2014 | Am. J. Transplant. | pmid:25179306 |
| Klintmalm GB | Immunosuppression, generic drugs and the FDA. | 2011 | Am. J. Transplant. | pmid:21794082 |
| Böger CA et al. | Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity. | 2006 | Am. J. Transplant. | pmid:16889550 |
| Shihab FS et al. | Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. | 2013 | Am. J. Transplant. | pmid:23167508 |
| Forns X and Navasa M | Cyclosporine A or tacrolimus for hepatitis C recurrence? An old debate. | 2011 | Am. J. Transplant. | pmid:21797970 |
| Tan HP et al. | Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. | 2006 | Am. J. Transplant. | pmid:16889606 |
| Wlodarczyk Z et al. | Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. | 2009 | Am. J. Transplant. | pmid:19681813 |
| Chisholm-Burns MA et al. | Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19681814 |
| Byrne GW et al. | Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. | 2005 | Am. J. Transplant. | pmid:15816881 |
| Schold JD and Kaplan B | AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19681827 |
| Lucey MR et al. | A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. | 2005 | Am. J. Transplant. | pmid:15816894 |
| Pillebout E et al. | Renal histopathological lesions after orthotopic liver transplantation (OLT). | 2005 | Am. J. Transplant. | pmid:15816895 |
| Arnold R et al. | Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. | 2013 | Am. J. Transplant. | pmid:23841745 |
| Hirsch HH et al. | BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12. | 2016 | Am. J. Transplant. | pmid:26639422 |
| Woodle ES et al. | A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. | 2005 | Am. J. Transplant. | pmid:15636625 |
| Mian AN et al. | Mycoplasma hominis septic arthritis in a pediatric renal transplant recipient: case report and review of the literature. | 2005 | Am. J. Transplant. | pmid:15636628 |
| Gregoor PS and Weimar W | Tacrolimus and pure red-cell aplasia. | 2005 | Am. J. Transplant. | pmid:15636632 |
| Busque S et al. | Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. | 2009 | Am. J. Transplant. | pmid:19660021 |
| Bohl DL et al. | Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. | 2005 | Am. J. Transplant. | pmid:16095500 |
| Kasahara M et al. | Living-donor liver transplantation for hepatoblastoma. | 2005 | Am. J. Transplant. | pmid:16095502 |
| Lemahieu WP et al. | Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. | 2005 | Am. J. Transplant. | pmid:16095503 |
| Gao R et al. | Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells. | 2007 | Am. J. Transplant. | pmid:17391142 |
| Tremblay S et al. | A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. | 2017 | Am. J. Transplant. | pmid:27340950 |
| Madeleine MM et al. | HPV-related cancers after solid organ transplantation in the United States. | 2013 | Am. J. Transplant. | pmid:24119294 |
| Lemahieu WP et al. | CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. | 2004 | Am. J. Transplant. | pmid:15307840 |
| Vongwiwatana A et al. | Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. | 2004 | Am. J. Transplant. | pmid:14678043 |
| Bressollette-Bodin C et al. | A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. | 2005 | Am. J. Transplant. | pmid:15996241 |
| De Simone P et al. | Everolimus with reduced tacrolimus in liver transplantation. | 2013 | Am. J. Transplant. | pmid:23601137 |
| Augustine JJ et al. | Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. | 2005 | Am. J. Transplant. | pmid:15996247 |
| Filler G et al. | Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. | 2005 | Am. J. Transplant. | pmid:15996252 |
| Fan DM et al. | Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up. | 2015 | Am. J. Transplant. | pmid:25808777 |
| Shihab F et al. | Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus. | 2017 | Am. J. Transplant. | pmid:28141897 |
| Chodoff L and Hamberg KJ | Response to 'Different preparations of tacrolimus and medication errors'. | 2009 | Am. J. Transplant. | pmid:19392982 |
| Luther P and Baldwin D | Pioglitazone in the management of diabetes mellitus after transplantation. | 2004 | Am. J. Transplant. | pmid:15575920 |
| Cherukuri A et al. | An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. | 2012 | Am. J. Transplant. | pmid:22390816 |
| Dahm F et al. | Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. | 2004 | Am. J. Transplant. | pmid:15575921 |
| Pascher A et al. | Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial. | 2015 | Am. J. Transplant. | pmid:25677074 |
| Barth RN et al. | Vascularized bone marrow-based immunosuppression inhibits rejection of vascularized composite allografts in nonhuman primates. | 2011 | Am. J. Transplant. | pmid:21668624 |
| Chen G et al. | A synergistic effect between PG490-88 and tacrolimus prolongs renal allograft survival in monkeys. | 2006 | Am. J. Transplant. | pmid:16539628 |
| Guirado L et al. | Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. | 2011 | Am. J. Transplant. | pmid:21668633 |
| Grenda R et al. | A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. | 2010 | Am. J. Transplant. | pmid:20420639 |
| Mazariegos GV et al. | Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. | 2005 | Am. J. Transplant. | pmid:15643991 |
| Knechtle SJ et al. | Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. | 2009 | Am. J. Transplant. | pmid:19344431 |
| Bahra M et al. | MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. | 2005 | Am. J. Transplant. | pmid:15644002 |
| Asberg A et al. | Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. | 2010 | Am. J. Transplant. | pmid:20486914 |
| Hautz T et al. | Molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation. | 2010 | Am. J. Transplant. | pmid:20353468 |
| Montgomery SP et al. | Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. | 2002 | Am. J. Transplant. | pmid:12118862 |
| Ahsan N et al. | Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. | 2002 | Am. J. Transplant. | pmid:12118902 |
| van Hooff JP et al. | Glucose metabolic disorder after transplantation. | 2007 | Am. J. Transplant. | pmid:17511670 |
| Silva HT et al. | One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. | 2007 | Am. J. Transplant. | pmid:17217442 |
| Heffron TG et al. | Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. | 2007 | Am. J. Transplant. | pmid:17511684 |
| Moench C et al. | Tacrolimus monotherapy without steroids after liver transplantation--a prospective randomized double-blinded placebo-controlled trial. | 2007 | Am. J. Transplant. | pmid:17511685 |
| Patlolla V et al. | Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. | 2007 | Am. J. Transplant. | pmid:17564638 |
| Nijhoff MF et al. | Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression. | 2016 | Am. J. Transplant. | pmid:26288226 |
| Bunnapradist S et al. | Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. | 2013 | Am. J. Transplant. | pmid:23279614 |
| Ceschi A et al. | Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011. | 2013 | Am. J. Transplant. | pmid:23279718 |
| Toso C et al. | Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. | 2006 | Am. J. Transplant. | pmid:16611343 |
| Lacaille F et al. | Severe dysimmune cytopenia in children treated with tacrolimus after organ transplantation. | 2006 | Am. J. Transplant. | pmid:16611346 |
| Chamie K et al. | The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer. | 2008 | Am. J. Transplant. | pmid:18853950 |
| Tedesco-Silva H et al. | Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. | 2015 | Am. J. Transplant. | pmid:25988935 |
| Pech T et al. | Intestinal regeneration, residual function and immunological priming following rescue therapy after rat small bowel transplantation. | 2012 | Am. J. Transplant. | pmid:22974463 |
| Kaplan B and Kirk AD | Tacrolimus and sirolimus: when bad things happen to good drugs. | 2006 | Am. J. Transplant. | pmid:16827845 |
| McDonald RA et al. | Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. | 2008 | Am. J. Transplant. | pmid:18416737 |
| McAlister VC et al. | Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. | 2006 | Am. J. Transplant. | pmid:16827858 |
| Gallon L et al. | Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. | 2006 | Am. J. Transplant. | pmid:16827862 |
| Grenda R et al. | A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. | 2006 | Am. J. Transplant. | pmid:16827869 |
| Vanhove T et al. | High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. | 2016 | Am. J. Transplant. | pmid:27013142 |
| Barbas AS et al. | Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. | 2013 | Am. J. Transplant. | pmid:23331705 |
| Gatault P et al. | Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. | 2017 | Am. J. Transplant. | pmid:27862923 |
| Fujishiro J et al. | Influence of immunosuppression on alloresponse, inflammation and contractile function of graft after intestinal transplantation. | 2010 | Am. J. Transplant. | pmid:20642681 |
| Martinez F et al. | High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. | 2010 | Am. J. Transplant. | pmid:20642691 |
| Miller LW | Cardiovascular toxicities of immunosuppressive agents. | 2002 | Am. J. Transplant. | pmid:12392286 |
| Brennan DC et al. | Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. | 2005 | Am. J. Transplant. | pmid:15707414 |
| Chhabra D et al. | Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. | 2013 | Am. J. Transplant. | pmid:24007570 |